By extension, if FOXP3+ Tregs showed no increase in patients with CHB and in the tumor environment after pre-treatment, sequential IL-2 therapy (combined with immune checkpoint blockade) may have an application in the eradication of tumors such as hepatocellular carcinoma. This evidence concerns the gene FOXP3 and neoplasm.